Company intelligence / Profile preview

Kelonia Therapeutics

Boston, Massachusetts, United Stateskeloniatx.com ↗
Ownership
Private
Employees
~100
Development stage
Preclinical
01

Overview

Kelonia has presented preclinical data on its iGPS™ technology for in vivo CAR-T therapies for multiple myeloma treatment[5]

Therapeutic areas
Oncology
Modalities
Gene therapyin vivo CAR-T cell therapygenetic medicines
Industry
Biotech
02

Drug pipeline

3 assets

KLN-1010

1

2 more assets in the full pipeline.

03

Partnerships

Astellas Pharma Inc. (through Xyphos Biosciences)ElevateBio

Beyond the preview

Go deeper on Kelonia Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kelonia Therapeutics.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call